BALTIMORE, Sept. 2, 2019 /PRNewswire/ -- After Julie Odar's water broke at 16 weeks (Preterm Premature Rupture ofMembranes or PPROM), doctors advised that nothing could be done to safely continue the pregnancy. Against all odds, Julie managed to stay pregnant for 17 days before learning that her child had passed away; Julie delivered baby

FREMONT, Calif., Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, September 3, at 8:30 am Eastern Time

MILAN and BASEL, Switzerland, Sept. 2, 2019 /PRNewswire/ -- A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) agonist, may help to address the gap in managing the residual risk of heart attacks and strokes in high-risk patients, according to over 50 world-leading experts fro

PITTSBURGH, Sept. 2, 2019 /PRNewswire/ -- "I was working in my shop, and I grew tired of having to go into the house every time I needed to wash my hands," said an inventor from Missouri City, Texas. "This inspired me to develop a convenient mobile hand-washing station that can be set up and used wherever it is needed."

LUND, Sweden, Sept. 2, 2019 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that by virtue of the authorisation by the annual general meeting held on 22 May 2019, the board of directors of Hansa Biopharma AB (publ) has resolved to issue and immediately thereaft

WEXFORD, Ireland, Sept. 2, 2019 /PRNewswire/ -- The world famous medical journal The Lancet has published the results of a two year health impact trial in Bangladesh. Less than 5% of studies submitted to this peer reviewed journal are published.

MUENSTER, Germany, Sept. 2, 2019 /PRNewswire/ --At the 9th AFM BioMed Conference, Bruker Corporation (Nasdaq: BRKR) today announced the release of the

EAST HANOVER, N.J., Sept. 2, 2019 /PRNewswire/ -- Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto® (sacubitril/valsartan) in patients with heart failure with reduced ejection fraction (HFrEF). Results suggest that Entresto, an essential treatme

NEW YORK, Aug. 31, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Oasmia Pharmaceutical AB from October 23, 2015 through July 9, 2019, inclusive (the "Class Period") of the important September 27, 2019 lead plaint

SUMMIT, N.J., Aug. 31, 2019 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cel